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Introduction
Modern biomedical science is embodied in the principle 
of One Health, or the recognition that exploration of 
evolutionarily conserved genes and proteins in vivo and 
in vitro using animal models and cell lines, respectively, is 
a viable and robust means of understanding human 
health and disease [1]. Th e One Medicine concept was 
fi rst articulated by the German physician Virchow in the 
1860s [2]. Experimental cancer research is founded on 
fundamental discoveries made using primary and trans-
planted mouse breast cancer models [3]. To this arma-
mentarium, modern investigators have added cultured 
and xenografted human cell lines. While critical for discern-
ing fundamental cancer mechanisms, model systems 
present both opportunities and challenges for trans la-
tional medicine practitioners. Th ese opposing prospects 
are exemplifi ed in three primary themes within the 
current breast cancer literature, which are briefl y 
reviewed and integrated here: gene addiction; phenotypic 
plasticity, exemplifi ed by epithelial-to-mesenchymal 
transi tion (EMT); and cancer stem cells (CSC). In parti-
cular, the EMT phenomenon illustrates the interactions 
among these three themes.
Historical context
Most of the fundamental concepts underpinning gene 
addiction, phenotypic plasticity, CSC, and EMT are 
deeply embedded in the history of breast cancer research. 
As with many scientifi c questions, early investigations 
into these concepts were obscured by inconsistent termi-
nology and the resulting inability to link fi ndings 
identifi ed independently by numerous researchers. For 
example, the hypothesis that cancer originates from an 
embryonic stem cell was fi rst proposed in the late 1800s 
by Connheim and Virchow [4]. Connheim called the cells 
blastema, which Virchow erroneously proposed arose 
from the connective tissue [4].
Th e recognition of cellular plasticity can primarily be 
credited to the modern developmental biologists who 
described this epithelial-to-mesenchymal transition and 
coined the concept of EMT [5,6]. Medical scientists have 
only recently embraced EMT as a clinically signifi cant 
phenomenon in cancer biology. For example, descriptions 
of carcinosarcomas in the mouse mammary gland noted in 
1906 would be called EMT tumors 100 years later [7]. 
Similarly, the famed Spanish morphologist Cajal observed 
‘pear-like cells, not attached to each other’ in human breast 
cancer in the late 1800s that surely now would be noted as 
EMT [5]. In contrast, the concept of gene addiction in 
breast cancer is less than a decade old. Nevertheless, inte-
gration of gene addiction with pheno typic plasticity, EMT 
tumorigenesis, and CSC provides the key to an integrated 
mechanistic understanding of current breast cancer biology.
Gene addiction as the driver for cancer induction 
and cancer phenotypes
Th e reliance of cancer cells on expression of specifi c genes 
(gene addiction) has provided important mecha nistic 
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insight into the phenomena of plasticity, CSC, and EMT. 
Th e concept of gene addiction was primarily based on 
genetically engineered mouse (GEM) experiments in 
which conditional transgenic overexpression of onco-
genes rapidly induced tumors [8,9]. High intralesional 
oncogene levels were always coupled with neoplasia, 
while switching off  the oncogene expression led to tumor 
regression [10,11]. Prominent examples of such addiction 
in mouse breast cancer models include tumors driven by 
MYC, ERB2 (HER2-neu), and RASGRF1 (Ras) – onco-
genes that are also upregulated in a substantial fraction of 
human breast cancers [12,13]. With the recognition of 
key roles for other genes in modifying cancer phenotypes, 
cancer gene addiction has been broadened and recently 
divided into two categories: oncogene addiction, and 
non-oncogene addiction (NOA) [14]. Th e genes linked to 
NOA do not initiate cancer per se but instead play critical 
roles in cancer development and progression. Th e NOA 
genes encode a large variety of molecules involved in 
almost all critical signaling pathways. Notably, NOA 
genes are usually downregulated or lost in cancer, and 
thus fall under the broad classifi cation of tumor-
suppressor genes (TSGs).
It is important to recognize that cancer cell addiction 
to both oncogenes and NOA genes has a profound eff ect 
on the histomorphology of cancers [15], resulting in 
genotype-specifi c tumor phenotypes (Figure 1). For 
example, loss of cadherin-1 (CDH1, also termed E-
cadherin), a NOA gene, is associated with human lobular 
breast cancer [16] and leads to an identical pattern 
(phenocopy) in mouse mammary gland tumors 
(Figure  1A,B). In mice, overexpression of the Her2/Neu 
oncogene results in solid nodular tumors (Figure 1C) that 
mimic human comedo carcinoma [17], while enhanced 
expression of the Myc oncogene leads to hyperchromasia, 
an increased nuclear:cytoplasmic ratio, and enlarged 
nucleoli (Figure 1D). Th ese phenotypes are readily recog-
nized by an experienced pathologist.
Th e NOA concept includes the loss, mutation or 
downregulation of TSGs, such as BRCA1, BRCA2, PTEN, 
TP53 (p53), and RB1 (Rb) [14]. Th e traditional TSGs 
serve as gatekeepers (by preventing excess cell prolifera-
tion) or as caretakers (by repairing DNA to maintain 
genome integrity). More recently, a TSG class has been 
identifi ed that inhibits metastasis [18,19]. Loss of func-
tion for many TSGs has been linked to unique morpho-
logical phenotypes for subsets of mammary gland 
tumors. For example, BRCA1 is associated with medul-
lary breast carcinomas [20], Pten deletion is linked to 
adenomyoepithelial diff erentiation in murine mammary 
tumors (Figure 1E), TP53 mutations are associated with 
EMT in cancers of the breast and other organs [21], and 
Rb1 mutations induce neuroendocrine tumors in most 
organs, including the breast [22]. Specifi c molecular 
signatures can therefore be linked to particular structural 
phenotypes. Furthermore, the most important molecular 
determinants in defi ning the ultimate anatomy of malig-
nant breast tumors rests within the original genetic 
errors that are expressed in preneoplastic or non-invasive 
neoplastic lesions such as ductal carcinoma in situ in 
humans as well as mammary intraepithelial neoplasia in 
mice [23].
Figure 1. Breast tumor phenotypes are often associated with a 
specifi c gene addiction. (A) Tm((CDH1–/–)x(p53–/–)) mice develop 
cadherin-1 (Cdh1)-defi cient mammary tumors characterized by 
a single-fi le pattern of neoplastic epithelium infi ltrating a dense 
stroma [43]. (B) Lobular carcinoma of the human breast is a CDH1-
defi cient tumor that displays a similar growth pattern, with cords of 
neoplastic epithelium coursing through dense connective tissue. 
(C) Tg(cNeu) mice that overexpress the ErbB2 oncogene develop 
breast cancers having a solid, nodular growth pattern with relatively 
uniform oval nuclei and abundant red–orange cytoplasm. (D) Typical 
neoplastic mammary epithelial cells in Tg(cMyc) mice exhibit 
a high nuclear:cytoplasmic ratio along with large pleomorphic 
nuclei having coarse hyperchromatic chromatin and prominent 
nucleoli in response to overexpression of the c-Myc oncogene. 
This tumor has a glandular pattern that is rarely seen in Tg(cNeu) 
mice. (E) Adenomyoepithelioma from a Tm(Pten–/–) mouse that 
features small gland-like spaces surrounded by a highly cellular 
stroma in response to ablation of the Pten tumor suppressor gene. 
Note the reddish polar cytoplasm characteristic of the tumor cells. 
(F) A complex Type P tumor in a Tg(Wnt2) mouse illustrating the 
intricate growth patterns associated with uncontrolled overactivity 
in the canonical Wnt pathway. Note the central ductal structure 
with various neoplastic masses at the periphery. All fi gures were 
digitally captured using whole-slide imaging of hematoxylin and 
eosin-stained slides using the 10x or 20x objective; fi gures have been 
cropped to a similar size for ready comparison.
Cardiff  et al. Breast Cancer Research 2011, 13:216 
http://breast-cancer-research.com/content/13/5/216
Page 2 of 10
Genotype-specifi c phenotypes have been extended to 
include entire pathways [24]. An example of this capacity 
is the combined members of the Wnt signaling pathway 
[25,26]. In the canonical Wnt pathway, the many Wnt 
ligands bind their receptors to stabilize β-catenin, allow-
ing it to enter the nucleus to regulate the transcription of 
target genes that control cell fate and maintain the pluri-
potency of adult stem cells. Uncontrolled canonical Wnt 
signaling is a hallmark of cancer. In the mouse mammary 
gland, tumors resulting from disruption of the Wnt 
pathway (Wnt tumors) exhibit complex and hetero-
geneous phenotypes comprised of intermingled epithelial 
and mesenchymal derivatives (Figure 1F).
Linking the expression of specifi c oncogenes to 
neoplasm development provided signifi cant impetus to 
the notion of personalized molecular therapy. Th e basis 
of this concept is that tumors will regress if the initiating 
oncogene(s) is targeted with the appropriate drug. Th is 
premise was soon dispelled, however, by evidence in the 
mouse that certain oncogene-derived tumors frequently 
escape their oncogene addiction [27]. Although sobering, 
this escape from oncogene addiction has also provided 
an oppor tunity to explore one of the central problems in 
clinical oncology – the drug-resistant tumor. How do 
addicted tumors become drug resistant?
Additional acquired mutations in neoplasms from 
various tissues represent an obvious answer to this 
question. For example, human leukemias resistant to the 
tyrosine kinase inhibitor imatinib are associated with a 
mutant ABL1 (c-Abl) proto-oncogene [28]. Mouse tumors 
with Myc mut ations that were oncogene independent 
frequently have an activated Hras (K-ras) gene [29]. 
However, other mechanisms of enhanced malignancy, 
metastasis, and tumor resistance have emerged recently 
that also deserve consideration – namely, phenotypic 
plasticity and CSC.
Gene addiction, epithelial-to-mesenchymal 
transition, and phenotypic plasticity in breast cancer
Epithelial-to-mesenchymal transition is a common breast 
cancer phenotype
Escape from oncogene addiction was observed in GEMs 
that developed mammary tumors despite having lost 
expression of the oncogenic transgene. Th e neoplastic 
mammary gland epithelium formed tumors with many 
histomorphologic appearances. One category fi rst 
described in mouse models is the carcinosarcoma, now 
classifi ed generically as an EMT tumor [7,30]. Th ese 
masses are of epithelial origin but contain a substantial 
spindle cell component (Figure 2).
During the fi rst half of the twentieth century, these 
mixed neoplasms were believed to be artifacts of trans-
planting tumor tissue or cultured tumor cells into 
allogenic mice [30]. More recent research indicates that 
EMT tumors represent intraneoplastic dediff erentiation 
to a more embryonic state, where tumor cells have lost 
their pure epithelial attributes and gained some mesen-
chymal properties [31]. Contrary views to this premise 
have been expressed [32].
During both embryogenesis and tumor formation, 
EMT is characterized by transformation of plump epithe-
lium into fusiform (spindle-shaped) mesenchyme [31]. 
Th e EMT process has been described in detail in both 
mouse mammary development and tumorigenesis (see 
reviews in [33]). Th e process encompasses gradual dis-
rup tion of epithelial architec ture, resulting in disconti-
nuity of basement membranes, loss of cellular cohesion, 
altered apico-basal polarity, and assumption of spindloid 
cellular profi les. In addition to having altered morpho-
logy, spindle cells in mixed tumors express both epithelial 
(for example, cytokeratins) and mesenchymal (for exam-
ple, fi bronectin, smooth muscle actin, vimentin) cyto-
skeleton components, although the extent of marker 
expression tends to vary from region to region (Figure 2) 
[7,34]. Th e morphologic continuum observed in such 
tumors probably refl ects the ability of neoplastic mouse 
mammary epithelium to divide into daughter cells with 
distinct phenotypes: epithelioid and spindloid [29]. Of 
note is that the proportion between the two components 
has serious implications in proliferation and invasiveness 
of many cancers, especially those of the mouse mammary 
gland [34]. In human breast cancer, however, there is 
little agreement about exactly what constitutes EMT 
tumorigenesis [7,35]. Currently, the presence of EMT in 
human breast cancers is largely estab lished by specifi c 
EMT signatures on gene expres sion arrays with little 
attention to phenotype.
Th e occurrence of EMT within human breast tumors 
has been linked with malignant transformation and en-
hanced local and vascular invasiveness, and may refl ect the 
partial dediff erentiation of tumor cells [36]. Interest ingly, it 
appears that metastatic tumor cells undergo EMT to 
invade the vasculature and then rapidly restore an epi-
thelial phenotype via a reverse mesenchymal-to-epithelial 
transition (MET) to implant successfully at distant sites 
[37-39]. Active, bidirectional phenotypic plasticity in 
human EMT is therefore associated with enhanced malig-
nancy, distant dispersal, and poor prognosis [40].
Th e biological behavior of human and mouse EMT 
tumors in the mammary gland is not always identical. 
Mouse EMT tumors that arise spontaneously or develop 
from tissue culture transplants are locally aggressive but 
do not metastasize [7]. In contrast, EMT in the human 
breast is associated with widespread metastasis and is a 
strong indicator of a poor prognosis [40]. Several expla-
nations for this divergence between species have been 
postulated. Th e most obvious is that the morpho logic 
similarity between EMT tumors from humans and from 
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mice may represent a random happening, rather than an 
indication of shared molecular pathways. Supporting this 
premise is the fact that the transcriptional repressor 
SNAI1 (SNAIL), a major regulator of EMT, is over-
expressed in highly metastatic human breast cancers [41] 
but is decreased in metastasis of mice [34]. Another 
possibility is that mouse EMT spindle tumors represent a 
terminally diff erentiated lesion, and thus are not capable 
of metastasis [42]. If the latter proves true, development 
of therapeutic agents to induce terminal diff erentiation 
may represent a viable therapeutic strategy for human 
breast cancer patients.
CDH1 non-oncogene addiction defi nes the phenotype of 
breast tumors
Repression of CDH1 is the non-oncogene addiction that 
drives epithelial-to-mesenchymal transition
One of the key molecular examples of NOA in human 
breast carcinomas is the association between the EMT 
phenotype and altered cell-to-cell adhesion due to 
reduced CDH1 expression (Figure 2F) [39,42]. Like many 
of the NOA genes, CDH1 interacts with multiple signal-
ing pathways. Because of its apparent central role in 
human and mouse EMT tumorigenesis, CDH1 pertur-
bations will be discussed in detail as a prototype for NOA 
in mammary gland neoplasia.
CDH1 is a major component of adherens and tight 
junctional complexes. Loss of heterozygosity for CDH1 
was fi rst described in a unique breast cancer subtype, the 
lobular carcinoma, which is characterized by single fi les 
of epithelial tumor cells infi ltrating dense fi brous stroma 
(Figure 1B). Provocatively, GEM with null mutations of 
both Cdh1 and Trp53 targeted to the mammary gland 
developed breast tumors that are an exact phenocopy of 
human lobular carcinoma (Figure 1A,B) [43]. Reduced 
CDH1 expression may refl ect gene inactivation via muta-
tion [16], but more often results from epigenetic down-
regulation by CDH1 promoter hypermethylation [44] or 
Figure 2. Immunohistochemical phenotypes of epithelial-to-mesenchymal transition tumors in the mouse mammary gland in 
Tm(Stat1–/–) mice. Immunohistochemistry for various breast cell markers in serial sections of a mouse epithelial-to-mesenchymal transition (EMT) 
mammary tumor showing both epithelial and spindle cell components. Left: Cytokeratin (CK) staining for three epithelial markers: (A) luminal 
CK8/18, (C) basal CK5, and (E) progenitor CK6 cells. Right: Staining for two mesenchymal markers, (B) vimentin (VIM) and (D) smooth muscle actin 
(SMA), and (F) the epithelial junctional complex marker cadherin-1 (CDH1). (A), (B) The images are arranged to highlight the dual CK –VIM staining 
pattern of EMT tumors. The presence of (C), (D) basal cell antigens and (E) progenitor cell CK in conjunction with (F) loss of CDH1 characterizes 
the malignant breast epithelial population. All images were captured from whole-slide images acquired with the Aperio ScanScope XT (Aperio, 
Carlsbad, CA, USA) using the 20x objective. All markers were detected using an indirect immunoperoxidase procedure with diaminobenzidine as 
the chromagen and hematoxylin as the counterstain. (E) Bar = 100 μm. The Tm(Stat1–/–) mice were kindly provided by Dr RD Schreiber [109].
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from dysregulated CDH1 transcriptional repression 
[42,45].
Numerous molecules have been implicated in transient 
CDH1 repression. Prominent examples include ligands 
that act via serine/threonine kinase receptors, such as 
transforming growth factor beta, or tyrosine kinase 
receptors, such as epidermal growth factor, fi broblast 
growth factor, hepatocyte growth factor, insulin-like growth 
factor, platelet-derived growth factor, and vascular endo-
thelial growth factor. Expression of CDH1 is also con-
trolled by many transcription factors, including some 
members of the forkhead box (for example, FOXC1, 
FOXC2), basic helix–loop–helix (for example, TWIST1), 
and zinc fi nger (for example, SNAI1 (SNAIL), SNAI2 
(SLUG), ZEB1) transcription factor families [46,47], as 
well as by certain cytokines, such as IL-6 [48] and chemo-
kine (C-X-C motif ) ligand-12 (formerly termed stromal 
cell-derived factor-1) [49].
Th ese factors and the signaling pathways they aff ect 
often operate synergistically with each other, and with 
other molecules. Activation of NOTCH1, an important 
promoter of tumor angiogenesis, functions together with 
SNAI1-induced CDH1 repression to promote breast 
cancer metastasis [50], while vascular endothelial growth 
factor cooperates by boosting SNAI1 expression [51]. 
Reduction of CDH1 levels by fi broblast growth factor-1 
drives malignant transformation and EMT by inducing 
matrix metalloproteinase-3, the activity of which pro-
motes increased tumor cell motility [52]. Inhibition of 
CDH1 and SNAI1 is mediated by feedback from other 
proteins, such as downregulation of SNAI1 levels by 
glycogen synthase kinase-3 beta, which is in turn regu-
lated by the canonical Wnt pathway [53,54] or by small 
inhibitory microRNAs [55]. Some of these molecules are 
useful prognostic markers in human breast cancer, 
including C-X-C chemokine receptor type 4, which binds 
chemokine (C-X-C motif ) ligand-12 [49], and SNAI1 
[41]. Many of these same factors are controlled via the 
hedgehog signaling pathway [56], suggesting that hedge-
hog may also impact CDH1 expression in breast cancer.
Suppression of CDH1 is also associated with steroid 
hormone-responsive pathways. For example, estrogen 
receptor (ER)-positive tumors may develop an enhanced 
metastatic potential and become resistant to estrogen 
blockers (for example, tamoxifen) because C-X-C chemo-
kine receptor type 4-mediated signaling increases 
mitogen-activated protein kinase activity, which ultimately 
represses CDH1 [57,58]. Androgen receptor signaling, 
when combined with DNA modifi cations made by histone 
deacetylase-1, downregulates CDH1 in neoplastic breast 
epithelial cells, thereby impelling EMT and metastasis 
[59]. Th e impact of CDH1 in EMT is accompanied by 
reduced ERα (that is, ESR1) transcription, which is 
regulated by SNAI1 [60] and SNAI2 [61]; these two 
trans cription factors are regulated reciprocally by ERα. 
Interestingly, ERα expression in EMT is also found in the 
cytoplasm rather than exhibiting an exclusive localization 
to the nucleus as occurs in normal breast tissue [62]; the 
functional implications of this displacement are unknown.
Th e infl uence of steroid hormones in breast cancer is 
not limited to the neoplastic epithelium. Carcinoma-
associated fi broblasts express aromatase, an enzyme that 
augments in situ estrogen production, thereby providing 
carcinoma-associated fi broblasts with better tumor-
promoting capabilities that are not found in normal 
fi broblasts in non-neoplastic breast tissue [63]. Th is 
capability probably renders the neoplastic microenviron-
ment more suitable for the survival and expansion of the 
breast carcinoma cells.
EMT in the context of malignant transformation 
obviously involves other mechanisms besides CDH1 
represssion. One common fi nding is cadherin switching, 
where CDH1 is replaced by another type (usually CDH2 
(also called N-cadherin) or CDH11), resulting in 
increased cellular mobility [64,65]. Altered cadherins in 
tumors can be used as markers for EMT [64]. Further-
more, other junctional complex components involved in 
epithelial diff erentiation, such as claudins, occludins, and 
plakophilins, are also altered in breast cancer, especially 
along the invasive front [66]. As with CDH1, these other 
junctional proteins are also repressed by transcription 
factors of the basic helix–loop–helix and zinc fi nger 
families [42,45]. EMT may also result from disrupted 
interactions between integrins on neoplastic cells and 
their ligands within the basal lamina and/or extracellular 
matrix [67]. Alterations in cell–stromal interactions pro-
mote local invasion and facilitate metastasis. Additionally, 
mutations of the tumor suppressor gene Trp53 in GEM 
result in EMT [68], possibly via interference by Twist1 
[69]. Mutations of the human homolog gene TP53 are a 
common feature in breast carcinoma in humans but are 
not always associated with EMT [70].
Finally, current thinking in the research community is 
that a recently identifi ed breast tumor genotype, 
claudinlow, develops EMT as a prominent and repro-
ducible feature [71,72]. Th e expression level of various 
claudins in primary human breast cancers is usually 
higher than that of their regional lymph node 
metastases, suggesting that claudin reductions may 
contribute to tumor progression [73]. To our knowledge, 
the relation ship between the claudinlow genotype and 
altered expres sion of CDH1, or other molecules that can 
modify CDH1 levels, remains to be clarifi ed. None-
theless, claudinlow tumors are associated with the core 
molecular signature of EMT – for example, down-
regulation of CDH1 with concomitant upregulation of 
Goosecoid (GSC, a homeobox gene), SNAI2, trans-
forming growth factor beta 1 and TWIST1 – suggesting 
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a probable interaction between the pathways regulating 
CDH1 and claudin [47].
In summary, CDH1 is considered a central fi gure in 
clinical EMT tumorigenesis. As documented above, how-
ever, extensive, complex molecular interactions between 
CDH1 and the other key molecules are diffi  cult to evalu-
ate, let alone validate. Th e complexity coupled with the 
early state of NOA investigations guarantees confl icting 
notions about which are the key molecules driving the 
process and obscures mechanistic under standing of the 
entire process. Th e pathology community will have to 
continue searching for evidence that the EMT–MET 
paradigm is more than a molecular illusion.
Restoration of CDH1 promotes mesenchymal-to-epithelial 
transition
Metastatic seeding is the rate-limiting event for carci-
noma progression [39]. Th e current speculation is that 
EMT is required for initial tumor embolization, but that 
restoration of the original epithelial phenotype via MET 
is necessary for invading cancer cells to form viable 
metastases [74]. Th e MET process is hence reciprocal to 
EMT and includes both the reacquisition of an epithelial 
phenotype with the ability to form glands [74] and also 
the restoration of the molecular complement indicative of 
epithelial diff erentiation, such as CDH1 expression [39].
Th e molecular mechanisms of MET in breast cancer 
metastases remain unknown. Recent reports suggest that 
MET is induced in breast carcinoma cells by many 
signaling events: binding of signal transducer and 
activator of transcription-5 to its tyrosine kinase receptor, 
JAK2 [38]; reduced expression of phosphoglucose 
isomerase/autocrine motility factor [75]; and inhibition of 
SRC homology phosphotyrosyl phosphatase-2 (PTNP11 
in humans), a vital promitogenic and prosurvival trans-
ducer in the epidermal growth factor receptor signaling 
pathway [76]. All three pathways induce CDH1 expres-
sion and downregulate expression of mesenchymal 
markers (for example, fi bronectin, vimentin). Th e signal 
transducer and activator of transcription-5/JAK2 path-
way also reduces levels of SNAI1, an important CDH1 
repressor [38]. In spite of these known complex mole-
cular relationships, the presence of MET has rarely been 
documented in the clinical setting. It is not clear whether 
MET occurs in all metastatic clinical situations or 
whether the microarray and molecular data may refl ect 
associations rather than actual mechanisms.
Th ese proposed events remain mostly conjectural 
through guilt by association or documentation in rare 
tumor types. Th e popular reviews of the metastatic process 
present cartoons showing individual cells that undergo 
EMT and migrate through the connective tissue to invade 
the vasculature and be carried to a distant site where the 
reverse MET process occurs to ensure coloni zation. Not 
many pathologists have seen this pheno menon in 
traditional diagnostic or research samples [16]. Th e 
actual visualization of these events has been provided by 
Condeelis and coworkers, with intravital microscopy 
showing tumor cells migrating through the tissue with an 
escort of macrophages [77,78]. Most direct observations 
of intravascular malignant cells in standard microscopy, 
however, reveal these cells on rafts of fi brin clots [79,80] 
or as non-invasive intravascular emboli [81]. In other 
words, the clusters of cells that are molecularly able to 
invade and metastasize are probably small microscopic 
subsets that do not necessarily represent the entire 
neoplasm. Th is obser vation poses a problem in validating 
gene expression microarray signatures related to EMT 
because the overall tumor genetic make-up probably 
masks these rare events.
Cancer stem cells in breast cancer
In spite of the speculations of Virchow and Connheim, 
the stem cell hypothesis became lost in the fi eld eff ects 
hypothesis [4], and some medical textbooks of the 1950s 
taught tumor biology in the terms of dediff erentiation of 
mature cell populations. However, experimental proof 
eventually emerged that most cancers were clonal [3]. In 
mammary tumor biology, Joe Leighton and Barry Pierce 
provided evidence of a rare stem cell population in mouse 
mammary tumors that gave rise to neoplasms [3]. Th e 
inherent plasticity of the CSC in the context of the 
mammary gland was discussed in the 1970s by Beatrice 
Mintz [3]. Th e ultimate demonstration of plasticity was 
given by Gail Martin using blastocyts injected with 
terato carcinoma cells to produce normal healthy mouse 
pups [82].
Tumor heterogeneity has become an important theme 
of breast cancer research, suggesting that tumors consist 
of multiple clonally derived subpopulations [57,83,84]. 
Large subpopulations of tumor cells are either capable of 
expansion or are terminally diff erentiated, while only a 
small subset of primitive, pluripotent CSC is capable of 
self-renewal, asymmetrical mitoses, and multilineage-
specifi c diff erentiation [83].
Human breast CSC are usually associated with a 
CD44+/CD24−/low signature [83]. Expression of these 
surface molecules is aff ected by numerous genetic and 
epigenetic factors [85], however, and new markers (for 
example, aldehyde dehydrogenase-1, multidrug-resis tance 
proteins) are regularly being linked to self-renewability 
[83,86,87]. Accordingly, a defi nitive molecular phenotype 
for breast CSC has not been determined.
Th e origin of breast CSC also remains uncertain. 
Competing hypotheses are that CSC arise by de-
diff erentiation of proliferation-competent epithelial cells, 
or by oncogenic mutations in normal stem cells [88]. At 
least four genetically distinct breast cancer subtypes have 
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been defi ned by microarray profi ling [89], and at least 
two types of stem cells have been identifi ed within these 
subtypes – basal progenitors and luminal progenitors 
[90]. At present, the former population is considered to 
be a better candidate for breast CSC [83]. Claudinlow 
tumors, however, have been hypothesized to arise from 
an even earlier breast epithelial precursor than either 
basal-like or luminal progenitor cells [71,72]. Further-
more, some evidence suggests that the CSC are present 
in the early premalignant stages [91].
Comparable stem cell subsets have been defi ned in 
mouse mammary tumors, which share many conserved 
genes with their human counterparts [92]. A recent study 
in developing (prenatal and early postnatal) mice suggests 
that diff erent cohorts of cultured, poorly diff erentiated 
breast epithelial cells exhibit distinct patterns of cyto-
keratin (CK) expression. In particular, CK5 occurs in 
basal cells, CK6 marks multipotent progenitor cells in the 
basal layer, CK8 is found in luminal cells, and CK14 is 
confi ned to myoepithelial cells; small populations are 
positive for both CK6 and CK14 [93] (Figure 2). Th e 
CK6+ breast epithelium population has been both pro-
posed [94] and denied [95] as another marker for mam-
mary gland stem cells. Importantly, unique subpopu-
lations of CSC appear capable of giving rise to diff erent 
breast cancer variants in both humans and mice [92]. If 
some or all of the above-mentioned CK patterns are 
eventually confi rmed, these intermediate fi laments could 
be used as molecular indicators for functionally unique 
breast epithelial cell types.
Lastly, breast CSC are presumed to thrive only in 
specifi c microenvironmental niches [57] due to the 
availability of the many supporting factors that aff ect 
stem cell numbers and function. For example, the popu-
lations of both normal stem cells and CSC are charac-
terized by phosphatidylinositol 3-kinase activation 
resulting from HER2 amplifi cation [96] in conjunction 
with decreased PTEN expression and decreased 
canonical Wnt/β-catenin interactions [97]. Signaling via 
Sonic Hedgehog [98] or NOTCH [99] also promotes self-
renewal of cultured human mammary stem cells. Th e 
presence of transforming growth factor beta augments 
CSC motility and invasiveness [100]. Th e tumor micro-
environment is also important in CSC biology because 
many factors that support cancer growth, hormone 
resistance, immune evasion, and metastasis are produced 
by stromal cells, such as chemokine (C-X-C motif ) 
ligand-12 by mesenchymal stem cells [83,101] and 
carcinoma-associated fi broblasts [102].
Phenotypic plasticity is linked to cancer stem cell 
generation and competence
Local invasiveness and metastasis are governed by 
numerous factors, including the heterogeneity of cell 
subsets within the primary tumor [57,83,84], the inter-
action of tumor cells with the microenvironment [103], 
and the unique combination of cell signaling factors 
aff ecting the migrating metastatic cells (seeds) and the 
colonization sites (soil) [104]. Th e tendency to undergo 
EMT is one such factor, as this process generates multiple 
epithelial subsets with divergent states of stemness 
relative to more diff erentiated cells [105].
Several lines of evidence support the link between 
EMT and CSC in breast cancer. First, EMT induction 
endows normal and transformed mammary epithelial 
cells with stem cell properties, including the ability to 
self-renew and effi  ciently initiate tumors [106]. Second, 
neoplastic breast epithelium undergoing EMT exhibits a 
CD44+/CD24−/low genotype that is consistent with the 
proposed molecular signature of breast CSC [72,107]; 
this signature has also been linked to the claudinlow 
genotype [72]. Examples include the induction of CSC 
through EMT-driven activation of the Ras-mitogen-
activated protein kinase pathway [85] as well as via 
overexpression of SNAI1 and TWIST, key regulators of 
EMT [46].
Existing data suggest that the EMT program can trigger 
generation of breast CSC. One intriguing possibility is 
that EMT foments inherently diff erent CSC subtypes that 
are responsible for the initiation and progression of 
breast cancers with divergent patterns of progression and 
metastasis. Th e divergent patterns are exemplifi ed by the 
ability of one oncogene (Myc) to generate mouse 
mammary tumors with diff erent phenotypes [108]. Given 
the obvious pheno typic complexity of human breast 
cancer, considerable work correlating EMT and 
phenotypic plasticity, specifi c gene addictions, and CSC 
biology will be required to produce innovative therapies 
to attack this dreaded disease.
Conclusion
Th erapeutic approaches to breast cancer increasingly rely 
on personalized approaches that identify and attack 
specifi c genes, proteins, or pathways. Such targeted treat-
ments depend on the concept of gene addiction (to over-
expressed oncogenes and/or reduced non-onco genes) as 
a driving force in tumor initiation and progression. Drugs 
aimed at particular genes have shown some promise, but 
tumor plasticity – perhaps residing in the rare cancer-
initiating stem cells – frequently leads to drug resistance 
and relapse, preventing a patient moving from temporary 
remission to permanent cure. Ultimate success in breast 
cancer therapy will rely on our recognition, under-
standing, and control of CSC and the gene addictions 
that control phenotypic plasticity of breast cancers.
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